



For patients with CV disease and type 2 diabetes*


Add JARDIANCE early to your treatment plan to accomplish more†



When added to standard of care^{††}

For patients with type 2 diabetes and CV disease†

JARDIANCE can allow you to extend patients' lives^{1,4,6}



For your patients with CV disease and type 2 diabetes*

Consider how SOON you can ACCOMPLISH MORE with JARDIANCE¹

In the EMPA-REG OUTCOME[®] trial, benefits started early with significance initially achieved at:



RRR in CV death: HR=0.62; 95% CI: 0.49, 0.77^{1,4}
RRR in hospitalisation for heart failure: HR=0.65; 95% CI: 0.50, 0.85; p=0.002^{1,4}
RRR in incident or worsening nephropathy: HR=0.61; 95% CI: 0.53, 0.70; p<0.001¹

¹ Jardiance is currently not indicated to reduce the risk of hospitalisation for heart failure.

² Jardiance is currently not indicated to reduce the incident or worsening of nephropathy.

³ Standard of care included CV medications and glucose-lowering agents given at the discretion of physicians

⁴ In addition to glucose lowering, JARDIANCE demonstrated reduction in weight and blood pressure; JARDIANCE is not indicated for weight loss or reduction in blood pressure.¹

⁵ Adult patients with insufficiently controlled type 2 diabetes, CAD, PAD, or a history of MI or stroke.

References: 1. Jardiance[®] Malaysia Prescribing Information. 2. Roden M, Weng J, Eilbracht J, et al; EMPA-REG MONO Trial Investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes Endocrinol.* 2013;1(3):208-219. 3. Häring HU, Merker L, Seewaldt-Becker E, et al; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. *Diabetes Care.* 2014;37(6):1650-1659. 4. Zinman B, Wanner C, Lachin J, et al; EMPA-REG OUTCOME[®] Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015;373(22):2117-2128. 5. Wanner C, Inzucchi S, Lachin J, et al; EMPA-REG OUTCOME[®] Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med.* 2016;375(4):323-334. 6. Fitchett D, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME[®] Investigators. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. *J Am Coll Cardiol.* 2018;71(3):364-367. 7. Claggett B, Lachin JM, Hantel S, et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease: survival estimates from the EMPA-REG OUTCOME trial. *Circulation.* 2018;138:1599-1601. 8. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycaemic control. *Circulation.* 2018;138:1904-1907. 9. Jardiance Duo[®] Malaysia prescribing information. 10. Häring HU, Merker L, Seewaldt-Becker E et al; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. *Diabetes Care.* 2014;37:1650-1659. 11. Hadjadj S, et al. ADA 2015; Poster 19B, LB. 12. Kohler S, Zeller C, Ilijev H, Kaspers S. Safety and tolerability of empagliflozin in patient with type 2 diabetes: pooled analysis of phase I-III clinical trials. *Adv Ther* 2017;34(7):1707-1726.

For healthcare professionals only.



Boehringer Ingelheim (Malaysia) Sdn. Bhd.
Registration no. 198601000452 (149591-H)
Suite 15-5 Level 15, Wisma UOA Damansara II,
No. 6, Jalan Changkat Semantan, Damansara Heights,
50490 Kuala Lumpur.
Tel: +603 2092 0088 Fax: +603 2095 2818



Scan QR Code to access JARDIANCE[®] and JARDIANCE DUO[®] latest prescribing information